Biosyntia Closes A €11.5M Series B Round, Backed By Ecbf

Jun 07, 2022•about 3 years ago

Amount Raised

€11.5 Million

Round Type

series b

Description

Biosyntia has closed a Series B funding round of €11.5 million from a strong syndicate of experienced venture capital investors. The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds, the early-stage investment and company creation team of Novo Holdings A/S.

Company Information

Company

Biosyntia

About

The investment will allow the company to enter the production phase of its first-of-its-kind, natural and sustainable active ingredients as well as expand the pipeline of products. Using cutting-edge biotechnology and proprietary R&D tools and insights, the company is developing first-of-its-kind precision fermentation processes to replace fossil-based alternatives. The company today has several commercial partnerships, including collaborations with large market players such as Givaudan and WACKER. Biosyntia is an industrial biotech company delivering nature’s ingredients at scale both affordably and sustainably.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Biosyntia Closes A €11.5M Series B Round, Backed By Ecbf

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information